/HTGM

HTGM Stock - HTG Molecular Diagnostics, Inc.

Q: What is the analyst price target for HTGM?

Analyst price target information is not currently available for HTGM.

Q: What is HTGM's market cap?

Market capitalization information is not currently available for HTGM.

Healthcare|Medical - Diagnostics & Research|NASDAQ

$0.48+0.00%

+$0.00 (+0.00%) • Jun 14

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

SELL

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-65.3%upside

Target: $0.17

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HTGM

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.99

52W High$24.96

52W Low$0.46

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$6.37M	$8.91M	$8.55M	$19.20M	$21.50M
Gross Profit	$1.79M	$4.81M	$4.56M	$10.29M	$16.41M
Gross Margin	28.2%	54.0%	53.3%	53.6%	76.3%
Operating Income	$-20,829,596	$-17,823,826	$-19,585,639	$-18,960,105	$-16,159,231
Net Income	$-21,594,476	$-17,145,170	$-20,870,218	$-19,297,664	$-16,453,918
Net Margin	-339.2%	-192.5%	-244.1%	-100.5%	-76.5%
EPS	$-0.24	$-0.30	$-0.32	$-0.50	$-0.75

Company Overview

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq Oncology Biomarker Panel; HTG EdgeSeq ALKPlus assay EU; HTG EdgeSeq Pan B-Cell Lymphoma Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. has a governing agreement with QIAGEN Manchester Limited. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.

Visit Website

Earnings History & Surprises

HTGM

Beat Rate

38%

Last 16 quarters

Avg Surprise

-0.6%

EPS vs Estimate

Beats / Misses

6/6

4 met exactly

Latest EPS

$-2.28

Q2 2023

EPS Surprise History

Q3 21

+24.1%

$-7.20vs$-9.48

Q4 21

0.0%

$-7.20vs$-7.20

Q1 22

-11.3%

$-8.28vs$-7.44

Q2 22

-14.1%

$-9.72vs$-8.52

Q3 22

+6.9%

$-6.48vs$-6.96

Q4 22

+21.2%

$-4.92vs$-6.24

Q1 23

-119.0%

$-5.28vs$-2.41

Q2 23

-17.5%

$-2.28vs$-1.94

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 8, 2024	—	—	—	—
Q1 2024	Mar 28, 2024	—	—	—	—
Q4 2023	Nov 8, 2023	—	—	—	—
Q3 2023	Aug 10, 2023	$-1.84	—	—	—
Q2 2023	May 10, 2023	$-1.94	$-2.28	-17.5%	✗ MISS
Q1 2023	Mar 27, 2023	$-2.41	$-5.28	-119.0%	✗ MISS
Q4 2022	Nov 10, 2022	$-6.24	$-4.92	+21.2%	✓ BEAT
Q3 2022	Aug 11, 2022	$-6.96	$-6.48	+6.9%	✓ BEAT
Q2 2022	May 12, 2022	$-8.52	$-9.72	-14.1%	✗ MISS
Q1 2022	Mar 29, 2022	$-7.44	$-8.28	-11.3%	✗ MISS
Q4 2021	Nov 10, 2021	$-7.20	$-7.20	0.0%	= MET
Q3 2021	Aug 12, 2021	$-9.48	$-7.20	+24.1%	✓ BEAT
Q2 2021	May 13, 2021	$-11.40	$-9.60	+15.8%	✓ BEAT
Q1 2021	Mar 25, 2021	$-13.50	$-11.16	+17.3%	✓ BEAT
Q4 2020	Nov 10, 2020	$-12.60	$-12.60	0.0%	= MET
Q3 2020	Aug 11, 2020	$-14.40	$-14.40	0.0%	= MET
Q2 2020	May 13, 2020	$-14.40	$-14.40	0.0%	= MET
Q1 2020	Mar 25, 2020	$-14.40	$-1.80	+87.5%	✓ BEAT
Q4 2019	Nov 12, 2019	$-25.20	$-27.00	-7.1%	✗ MISS
Q3 2019	Aug 6, 2019	$-27.00	$-30.60	-13.3%	✗ MISS

Frequently Asked Questions about HTGM

What is HTGM's current stock price?

HTG Molecular Diagnostics, Inc. (HTGM) is currently trading at $0.48 per share. The stock has moved +0.00% today.

What is the analyst price target for HTGM?

The average analyst price target for HTGM is $0.17, based on 1 analyst.

What sector is HTG Molecular Diagnostics, Inc. in?

HTG Molecular Diagnostics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.

What is HTGM's market cap?

HTG Molecular Diagnostics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does HTGM pay dividends?

No, HTG Molecular Diagnostics, Inc. does not currently pay a dividend to shareholders.